ATHANA reaching first phase completion of nanoparticle antifungal Project
The ATHANA Alliance unites HAPILA with seven other Jena-based life sciences organisations that together cover the entire value chain for development of nanoparticle-delivered therapies.
The ATHANA alliance is approaching completion of the first phase of its work, which aims to develop novel antifungal therapies through targeted transport of active pharmaceutical ingredients (APIs) by an innovative nanoparticle technology. High‑potency active ingredient specialist CDMO HAPILA GmbH (HAPILA) is responsible for stability testing and regulatory issues relating to a future transition to the GMP (Good Manufacturing Practice) environment. With the main project milestone (proof of concept) close to being achieved, the founding phase of the project remains on schedule for completion by May 2026.
© 2026 HAPILA GmbH
Diese Webseite verwendet keine Tracking Tools. Durch Ihren Browser wird ein funktional notwendiges Cookie als Lesebestätigung gespeichert. Unsere Datenschutzrichtline enthält dazu weitere Details.
This website does not use any tracking tools. Your browser stores a cookie that is necessary for functionality to confirm that you have read this notice. Our Privacy Policy contains further details.
